Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vaxart Inc (VXRT)
NASDAQ:VXRT
Holding VXRT?
Track your performance easily
VXRT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.52 - $1.54
Previous Close$0.68
Volume1.82M
Average Volume (3M)4.16M
Market Cap
$152.44M
Enterprise Value$154.51M
Total Cash (Recent Filing)$19.80M
Total Debt (Recent Filing)$20.46M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Aug 08, 2024EPS Estimate
-$0.15Last Dividend Ex-Date
Nov 09, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding176,838,011
10 Day Avg. Volume16,169,434
30 Day Avg. Volume4,158,892
Standard Deviation0.57
R-Squared0.00364
Alpha0.09
Financial Highlights & Ratios
Price to Book (P/B)1.76
Price to Sales (P/S)1166.97
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue71.17
Enterprise Value/Gross Profit1.44K
Enterprise Value/Ebitda-1.89
Forecast
1Y Price Target
$2.50Price Target Upside269.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Vaxart News
PremiumCompany Announcements
Vaxart’s Q3 2024: Progress in Oral Vaccine Development
Bulls Say, Bears Say
Bulls Say
Financial PerformanceA registered direct offering at a premium indicates investor confidence and provides additional capital.
Government SupportVXRT announced receipt of the BARDA-funded project NextGen award of up to $453M to conduct a Phase IIb 10,000-subject head-to-head study testing VXRT’s oral COVID-19 vaccine candidate vs. an approved mRNA vaccine.
Product DevelopmentVaxart's oral Norovirus vaccine shows promise with the potential to vaccinate infants through breast milk, a unique approach compared to injectable vaccines.
Bears Say
LeadershipAnnouncement of CEO resignation could indicate potential leadership instability.
LeadershipAnnouncement of CEO resignation, with long-time BOD chair, Mike Finney, taking on the role.
RegulatoryThere is a general lack of precedent for the clinical development path for first-in-indication vaccines, presenting uncertainty in the approval process.
---
Ownership Overview
46.98% Insiders
5.63% Mutual Funds
3.46% Other Institutional Investors
43.92% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VXRT FAQ
What was Vaxart Inc’s price range in the past 12 months?
Vaxart Inc lowest stock price was $0.52 and its highest was $1.54 in the past 12 months.
What is Vaxart Inc’s market cap?
Currently, no data Available
When is Vaxart Inc’s upcoming earnings report date?
Vaxart Inc’s upcoming earnings report date is Aug 08, 2024 which is 116 days ago.
How were Vaxart Inc’s earnings last quarter?
Vaxart Inc released its earnings results on May 13, 2024. The company reported -$0.14 earnings per share for the quarter, the consensus estimate of -$0.14 by $0.
Is Vaxart Inc overvalued?
According to Wall Street analysts Vaxart Inc’s price is currently Undervalued.
Does Vaxart Inc pay dividends?
Vaxart Inc pays a Notavailable dividend of $12.188 which represents an annual dividend yield of N/A. See more information on Vaxart Inc dividends here
What is Vaxart Inc’s EPS estimate?
Vaxart Inc’s EPS estimate is -$0.15.
How many shares outstanding does Vaxart Inc have?
Vaxart Inc has 227,425,490 shares outstanding.
What happened to Vaxart Inc’s price movement after its last earnings report?
Vaxart Inc reported an EPS of -$0.14 in its last earnings report, expectations of -$0.14. Following the earnings report the stock price went up 4.878%.
Which hedge fund is a major shareholder of Vaxart Inc?
Among the largest hedge funds holding Vaxart Inc’s share is RA Capital Management. It holds Vaxart Inc’s shares valued at 20M.
---
Vaxart Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (269.55% Upside)
$2.50 (269.55% Upside)
Hedge Fund Trend
Increased
By 15.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $13.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.77%
12-Months-Change
Fundamentals
Return on Equity
-112.40%
Trailing 12-Months
Asset Growth
-31.71%
Trailing 12-Months
Company Description
Vaxart Inc
Biota Holdings Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.
---
VXRT Earnings Call
Q1 2024
0:00 / 0:00
---
VXRT Stock 12 Month Forecast
Average Price Target
$2.50
▲(269.55% Upside)
Technical Analysis
Best Analysts Covering VXRT
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
-11.74%
reiterated a buy rating 5 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -11.74% per trade.
---